Mirum reports positive Phase 3 LIVMARLI results and plans 2027 filing

Mirum Pharmaceuticals said on October 12 that its Phase 3 EXPAND trial of LIVMARLI met its primary and secondary endpoints in ultra-rare cholestatic liver diseases. In the pediatric primary analysis, maralixibat improved the worst-daily itch score by 1.81 points from baseline versus 0.83 points for placebo, producing a 0.98-point placebo-adjusted difference with p=0.0004. Mirum reported no new safety signals and plans to submit a U.S. supplemental New Drug Application in the first half of 2027.

The results give Mirum clinical support for seeking a broader LIVMARLI label, including potential use in biliary atresia, but any expansion still requires FDA review. The filing would extend the drug beyond its existing approved uses if regulators authorize it.

  • 1EXPAND included 52 participants, with 46 children and six adults.
  • 2Among pediatric patients, the itch-score improvement was 1.81 points with maralixibat versus 0.83 points with placebo, for a 0.98-point treatment difference and p=0.0004.
  • 3The native-liver biliary atresia subgroup showed a 1.15-point treatment difference in itch-score change, with p=0.0002.
  • 4Mirum plans to submit the U.S. supplemental New Drug Application in the first half of 2027.
  • 5No new safety signals were observed, according to Mirum.
  • Material 11 refers to an early 2024 supplemental filing, which conflicts with the 2027 timing reported by materials 4, 5, 7, 8, 11 and 12; the 2024 date appears inconsistent with the other event reports.

Sources